Catatonia Clinical Trial
Official title:
Catatonia in Ugandan Children With Nodding Syndrome and Effects of Treatment With Lorazepam: A Pilot Study
Nodding Syndrome is an enigmatic neuropsychiatric syndrome affecting children and adolescents mostly in Eastern Africa. The symptoms of Nodding Syndrome and catatonia seem to overlap. The researchers' objectives in this study were to investigate the presence and types of catatonic symptoms in children with Nodding Syndrome and observe their response to one or two doses of lorazepam, the first-line treatment for catatonia.
In this pilot study, the investigators examined a convenient sample of children and
adolescents with Nodding Syndrome (NS) for catatonic symptoms using standardized criteria.
The investigators also tested whether oral lorazepam (LZP) administered to those who
qualified to have pediatric catatonia would alleviate symptoms. This was a cross-sectional
descriptive study of catatonia in NS patients in Northern Uganda and an exploratory study of
using one or two doses of lorazepam as a catatonia test.
All the children with confirmed NS that had 2 or more of symptoms of catatonia were
recruited to undergo the catatonia test using oral Lorazepam EG® (n.v. Eurogenerics s.a.
Brussels, Belgium) using the 1 mg formulation tablets. It was proposed to perform a
catatonia test using Lorazepam (LZP) as first choice medication, as this is the medication
that has been used most commonly in pediatric catatonia.
The amount of drug given was based on the weight of the child. The lower dose (0.5 mg) was
used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as
the starting dose for patients with >30 kg body weight.
A positive response to a catatonia test consisted of a reduction in catatonic symptoms, 30
or 60 minutes later, by at least 50% .Positive responses were documented by video footage
before and after administration of LZP.
If no response to the initial dose of LZP, was observed after one hour, a second
administration of the same medication at double the dose was given. Catatonia was again
assessed at 30 and 60 minutes thereafter. If no response was observed, the test was
considered negative.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02868879 -
Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia
|
||
Recruiting |
NCT06176456 -
Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia
|
N/A | |
Withdrawn |
NCT02945423 -
Improving the Understanding of Catatonia in Autism
|
||
Terminated |
NCT02734498 -
Prospective Treatment Study of Catatonia Patients
|
N/A | |
Recruiting |
NCT04530734 -
Blood Concentration in Lorazepam and Treatment in Adult Catatonia
|
||
Not yet recruiting |
NCT06139432 -
Catatonia: Effectiveness of Transcranial Direct Current Electrostimulation (CATATOES)
|
N/A | |
Recruiting |
NCT06016764 -
Use of MRI and cTBS for Catatonia in Autism
|
Phase 1 | |
Recruiting |
NCT04828226 -
Clonidine to Prevent Delirium After Electroconvulsive Therapy.
|
Phase 4 | |
Recruiting |
NCT04335916 -
Survey on Pre-ECT Evaluation and ECT Application
|